Skip to main content

Table 1 General characteristics of male and female T2DM patients and non-diabetic subjects

From: Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients

Gender/characteristic Female Male
Non-diabetic T2DM Non-diabetic T2DM
Number of females 149 150 149 150
N in category, (%)
 Hypertension 47 (31.5 %) 63 (42.0 %) 36 (24.5 %) 69 (46.0 %)ł
 Cardiovascular disease 6 (4.0 %) 14 (9.3 %) 8 (5.4 %) 22 (14.7 %)ł
 Anti-hypertensive Medications
  Diuretics 2 (1.3 %) 2 (1.3 %) 2 (1.3 %) 7 (4.7 %)
  β blocker 4 (2.7 %) 12 (8.0 %)* 3 (2.0 %) 7 (4.7 %)
  Calcium channel blocker 7 (4.7 %) 24 (16.0 %) 9 (6.0 %) 32 (21.3 %)ǂ
  α blocker 4 (2.7 %) 11 (7.3 %) 0 (0 %) 17 (11.3 %)§
  ACE inhibitors/ARB 3 (2.0 %) 7 (4.7 %) 2 (1.3 %) 14 (9.3 %)ǂ
 Lipid lowering treatment 4 (2.7 %) 2 (1.3 %) 4 (2.7 %) 22 (14.7 %)ǂ
 Anti-diabetic treatment
  Insulin NA 20 (13.3 %) NA 22 (14.7 %)
  Sulfonylureas NA 61 (40.7 %) NA 32 (21.3 %)
  Metformin NA 94 (62.7 %) NA 62 (41.3 %)
  α glycosidase inhibitors NA 70 (46.7 %) NA 42 (28.0 %)
Mean (SD)
 Age (years) 52.9 (8.2) 56.6 (6.0)§ 53.8 (8.3) 54.5 (10.9)
 Body mass index (kg/m2) 26.2 (3.9) 26.4 (4.0) 25.2 (4.1) 26.5 (3.4)ł
 Systolic pressure (mm Hg) 131.8 (20.8) 138.8 (17.8)ł 133.8 (18.9) 135.2 (19.8)
 Diastolic pressure (mm Hg) 76.8 (10.6) 77.1 (11.2) 78.9 (12.1) 82.7 (10.8)ǂ
 eGFR (ml/min/1.73 m2) 131.4 (28.6) 116.8 (32.9)§ 118.1 (28.3) 105.6 (42.5)ł
 Total cholesterol (mg/dL) 195.9 (35.4) 195.1 (35.8) 187.0 (29.3) 176.8 (40.0)*
 LDL cholesterol (mg/dL) 118.3 (35.7) 121.4 (32.2) 111.3 (24.8) 108.5 (34.0)
 HDL cholesterol (mg/dL) 54.6 (12.8) 49.8 (9.7)ǂ 52.9 (13.8) 43.8 (13.9)§
 Fasting blood glucose (mmol/L) 5.0 (0.4) 8.3 (2.4)§ 5.1 (1.5) 8.9 (2.8)§
Geometric mean (IQR)
 Triglyceride (mg/dL) 111.5 (81.4–176.1) 123.7 (117.8–129.8) 106.0 (100.3–112.0) 150.8 (140.4–161.9)§
 Insulin (pmol/L) 50.9 (37.2–71.4) 58.9 (56.2–63.1)* 38.5 (36.4–40.7) 33.6 (30.3–37.2)
 Homa-β 92.0 (76.2–110.8) 41.7 (38.9–43.7)§ 75.5 (71.9–79.4) 24.1 (22.0–26.4)§
 Homa-IR 0.97 (0.69–1.32) 1.25 (0.80–1.91)§ 0.77 (0.47–1.14) 0.78 (0.29–1.50)
  1. eGFR estimated glomerular filtration rate; ACE inhibitors Angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blocker; LDL low-density lipoprotein; HDL high-density lipoprotein; Homa-βand Homa-IR were computed by Homeostasis Model Assessment algorithm (http://www.dtu.ox.ac.uk/homacalculator/) using fasting insulin and fasting blood glucose; IQR interquartile range
  2. * p ≤ 0.05; ł p ≤ 0.01; ǂ p ≤ 0.001; and § p ≤ 0.0001 when compared with sex-matched controls